论文部分内容阅读
目的探讨吉西他滨联合长春瑞滨方案治疗蒽环类和(或)紫杉类药物耐药性晚期乳腺癌的疗效与安全性。方法 36例对蒽环类和(或)紫杉类耐药性晚期乳腺癌患者,接受吉西他滨1000 mg/m2,静脉滴注,第1天、第8天,长春瑞滨25 mg/m2,静脉滴注,第1天、第8天,联合化疗,21 d为1周期。至少应用2个周期,最多接受6个周期的化疗。以WHO标准评价疗效和毒性。结果 36例患者中,完全缓解(CR)2例(5.6%),部分缓解(PR)17例(47.3%),疾病稳定(SD)10例(27.8%),疾病进展(PD)7例(19.4%),有效率(CR+PR)52.9%,中位疾病进展时间(TTP)8.8个月。主要不良反应为骨髓抑制、末梢神经毒性、消化道反应,均为可逆性。结论吉西他滨联合长春瑞滨方案是治疗蒽环类或紫杉类耐药性晚期乳腺癌的有效方案,不良反应轻,值得临床推广。
Objective To investigate the efficacy and safety of gemcitabine plus vinorelbine regimen in the treatment of anthracycline and (or) taxane-resistant advanced breast cancer. Methods Thirty-six patients with anthracycline and (or) taxane-resistant advanced breast cancer received gemcitabine 1000 mg / m 2 intravenously, on day 1, day 8, vinorelbine 25 mg / m 2, Instillation, day 1, day 8, combination chemotherapy, 21 d for 1 cycle. Apply at least 2 cycles and receive up to 6 cycles of chemotherapy. To evaluate the efficacy and toxicity of WHO standards. Results Of the 36 patients, 2 were complete remission (CR) (5.6%), 17 were partial remission (47.3%), 10 were stable disease (SD), 27 were disease recurrence (7.8% 19.4%), effective rate (CR + PR) 52.9%, and median time to progression of disease (TTP) 8.8 months. The main adverse reactions are myelosuppression, peripheral neurotoxicity, gastrointestinal reactions, are reversible. Conclusion The combination of gemcitabine and vinorelbine is an effective regimen for the treatment of anthracycline-resistant or taxane-resistant advanced breast cancer with mild adverse reactions and is worthy of clinical promotion.